The Dutch biotech Kiadis and Montreal-based Celmed BioSciences say they will merge operations, both of which are focused on new oncology therapies. The merged company will operate as Kiadis Pharma with headquarters in the Netherlands and operations in Canada and Europe. Financial details were kept under wraps.
The new Kiadis Pharma "has exceptionally strong credentials in oncology with over five years of clinical patient data that allows us to further strengthen our products and accelerate development," said Manja Bouman, CEO of Kiadis BV.
- check out the press release on the merger